Industries > Pharma > Antithrombin Market Report to 2031
Antithrombin Market Report to 2031
By Source (Human, Goat Milk, Others), By Application (Therapeutics, Research, Diagnostic, Others), By Type (Anticoagulants, Antiplatelet, Thrombolytic Drugs), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa)
Global Antithrombin Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Antithrombin market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Global Antithrombin report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antithrombin Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antithrombin Market by Source
• Human
• Goat milk
• Others
Antithrombin Market by application
• Therapeutics
• Research
• Diagnostics
• Others
Antithrombin Market by Type
• Anticoagulant
• Antiplatelet
• Thrombolytic Drugs
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antithrombin Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antithrombin Market with forecasts for by Source, by application and by type each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antithrombin Market report helps you
In summary, our 260+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antithrombin Market, with forecasts by Source, by application, and by Type each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antithrombin market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for the major companies involved in the Global Antithrombin Market. Some of the company’s profiled in this report include-
• Grifols, S.A
• Takeda Pharmaceutical Company Limited
• LFB Biotechnologies S.A
• Scripps Laboratories,
• Octapharma AG,
• Thermo Fisher Scientific
• Siemens AG
• Axis-Shield Diagnostic Ltd.
• Lee Bio solutions
• CSL Limited
• Kedrion S.p.A.
• Dem ilac Inc
• Kyowa Kirin Co., Ltd.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
Our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global anticoagulants market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antithrombin Market Report to 2031: By Source (Human, Goat Milk, Others), By Application (Therapeutics, Research, Diagnostic, Others), By Type (Anticoagulants, Antiplatelet, Thrombolytic Drugs), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antithrombin Market
2.1. Antithrombin Market Definition
2.2. By Source Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Type Submarkets Definitions
3. Antithrombin Market Overview
3.1. Global Antithrombin Size and Forecast by Region
3.2. Global Antithrombin Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Prevalence of Hereditary Antithrombin Deficiency.
3.3.1.2. Increasing Coagulation Disorders
3.3.1.3. Growing Adoption of Diagnostic Kits, Reagents with Antithrombin Deficiency.
3.3.1.4. Bleeding Episodes During Surgical Procedures.
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost of Antithrombin Therapy
3.3.2.2. Complication Associated with use of Oral Anticoagulants.
3.3.3. Opportunities
3.3.3.1. Technological Advancement and Rising Investment In R&D
3.3.3.2. Increasing Cardiovascular Disease & Ageing Population.
3.3.3.3. Increasing FDA Approval of Anticoagulants Drugs for Clinical Purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antithrombin Market Analysis and Forecast 2021-2031, By Source (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Human
4.1.2. Goat milk
4.1.3. Others
5. Global Antithrombin Market Analysis and Forecast 2021-2031, By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Therapeutics
5.1.2. Research
5.1.3. Diagnostics
5.1.4. Others
6. Global Antithrombin Market Analysis and Forecast, 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Anticoagulant
6.1.2. Antiplateletst
6.1.3. Thrombolytic Drugs
7. North America Antithrombin Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antithrombin Market Size and Forecast By Source
7.3. North America Antithrombin Market Size and Forecast By Application
7.4. North America Antithrombin Market Size and Forecast By Type
7.5. U.S. Antithrombin Market
7.5.1. Increasing Prevalence of CVD and Cancer in The Region, Boosting the Market.
7.6. Canada Antithrombin Market
7.6.1. Health Canada Has Approved Rivaroxaban to Prevent from Stroke, Myocardial Infarction, and Cardiovascular Death.
8. Europe Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antithrombin Market Size and Forecast By Source
8.3. Europe Antithrombin Market Size and Forecast By Application
8.4. Europe Antithrombin Market Size and Forecast By Type
8.5. UK Antithrombin Market
8.5.1. Rising risk of bleeding in high-risk surgery in the region.
8.6. Germany Antithrombin Market
8.6.1. Increasing use of antithrombin in the region.
8.7. France Antithrombin Market
8.7.1. Growing demand for stroke prevention in patients in the region.
8.8. Rest of Europe Antithrombin Market
9. Asia Pacific Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antithrombin Market Size and Forecast By Source
9.3. Asia Pacific Antithrombin Market Size and Forecast By Technology
9.4. Asia Pacific Antithrombin Market Size and Forecast By Type
9.5. China Antithrombin Market
9.5.1. Increasing cigarette consumption rate in the region.
9.6. India Antithrombin Market
9.6.1. Increasing awareness & expanding healthcare in the region.
9.7. Japan Antithrombin Market
9.7.1. Rising ageing population in the region.
9.8. Rest of Asia Pacific Antithrombin Market
10. Latin America Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antithrombin Market Size and Forecast By Source
10.3. Latin America Antithrombin Market Size and Forecast By Application
10.4. Latin America Antithrombin Market Size and Forecast By Type
10.4.1. Brazil Antithrombin Market
10.4.1.1. Arterial and venous thrombosis significantly impact morbidity and mortality.
10.4.2. Mexico Antithrombin Market
10.4.2.1. Rising need for screening and diagnosis of antithrombin deficiency.
10.4.3. Rest of Latin America Antithrombin Market
11. MEA Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antithrombin Market Size and Forecast By Source
11.3. MEA Antithrombin Market Size and Forecast By Application
11.4. MEA Antithrombin Market Size and Forecast By Type
11.5. South Africa Antithrombin Market
11.5.1.1. High incidence of mortality due to cancer, in the region.
11.6. Rest of MEA Antithrombin Market
12. Companies in the Antithrombin Market
12.1.1. Grifols, S.A
12.1.2. Company Snapshot
12.1.3. Company Overview
12.1.4. Financial Performance (2015-2020)
12.1.4.1. Net Revenue
12.1.4.2. Geographical Revenue, 2020
12.1.5. Product Offerings
12.1.6. Recent Initiatives (2017-2020)
12.2. Takeda Pharmaceutical Company Limited
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. LFB Biotechnologies S.A
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Scripps Laboratories
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Octapharma AG
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Thermo Fisher Scientific
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Siemens AG
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Axis-Shield Diagnostic Ltd
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Lee Bio solutions
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. CSL Limited
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antithrombin Market Drivers & Restraints 2021
Table 7. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table63. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64 Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antithrombin Market Forecast By Type 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table91. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94 North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 106. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table110. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 140. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 141. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 146. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159 Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 162. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190 Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198 Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206 Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214 Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217 Leading 10 Antithrombin Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 218. Grifols, S.A Profile 2020 (CEO, HQ, Founded, Website)
Table 219. Grifols, S.A Antithrombin Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 220. Grifols, S.A Antithrombin Product Offering (Segment, Product Offerings)
Table 221. Baxter International Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 222. Baxter International Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 223. Takeda Pharmaceutical Company Limited Profile 2020 (CEO, HQ, Founded, Website)
Table 224. Takeda Pharmaceutical Company Limited Antithrombin Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 225. Takeda Pharmaceutical Company Limited Antithrombin Product Offering (Segment, Product Offerings)
Table 226. LFB Biotechnologies S.A Profile 2020 (CEO, HQ, Founded, Website)
Table 227. LFB Biotechnologies S.A Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 228. LFB Biotechnologies S.A Antithrombin Product Offering (Segment, Product Offerings)
Table 229. Octapharma AG Profile 2020 (CEO, HQ, Founded, Website)
Table 230 Octapharma AG, Antithrombin Product Offering (Segment, Product Offerings)
Table 231. Thermo Fisher Scientific Profile 2020 (CEO, HQ, Founded, Website)
Table 232. Thermo Fisher Scientific Antithrombin Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 233 Thermo Fisher Scientific Antithrombin Product Offering (Segment, Product Offerings)
Table 234. Siemens AG Profile 2020 (CEO, HQ, Founded, Website)
Table 235. Siemens AG Antithrombin Product Offering (Segment, Product Offerings)
Table 236. Axis-Shield Diagnostic Ltd. Profile 2020 (CEO, HQ, Founded, Website)
Table 237. Axis-Shield Diagnostic Ltd Antithrombin Product Offering (Segment, Product Offerings)
Table 238. Lee Bio solutions Profile 2020 (CEO, HQ, Founded, Website)
Table 239. Lee Bio solutions Antithrombin Product Offering (Segment, Product Offerings)
Table 240. CSL Limited Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 241. CSL Limited Total Company Sales 2015-2020 (US$M, AGR %)
Table 242. CSL Limited Product Offering (Segment, Product Offerings)
Table 243. Other Companies Involved in the Antithrombin Market (Company, Location)
LIST OF FIGURES
Figure 1. Antithrombin Market Type Overview
Figure 2. Antithrombin Market By Source Overview
Figure 3. Antithrombin Market By Application Overview
Figure 4. Antithrombin Market By Type Overview
Figure 5 Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 61. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 141. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antithrombin Market Forecast By Source2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M)
Figure 151. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 161. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M)
Figure 171. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
15. China Biologic Products Holdings, Inc.
16. Lundbeck Inc
17. Axon Lab AG
18. Affinity Biologicals, Inc.
19. Sigma-Aldrich, Inc.
20. Abbott Laboratories
21. Baxter International Inc.
22. AstraZeneca plc
23. Bayer AG.
24. Boehringer Ingelheim GmbH
25. Eli Lilly and Company
26. Bristol-Myers Squibb Company
27. Merck & Co., Inc.
28. Genentech Inc.
29. GlaxoSmithKline plc
30. Pfizer, Inc.
31. Sanofi S.A
32. Novartis AG
33. Daiichi Sankyo Company
34. Aspen Holdings
35. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
36. Portola Pharmaceuticals, Inc.
37. Lunac Therapeutics
38. The Medicines
39. United Therapeutics
40. Otsuka Pharmaceutical
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antithrombin Market
2.1. Antithrombin Market Definition
2.2. By Source Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Type Submarkets Definitions
3. Antithrombin Market Overview
3.1. Global Antithrombin Size and Forecast by Region
3.2. Global Antithrombin Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Prevalence of Hereditary Antithrombin Deficiency.
3.3.1.2. Increasing Coagulation Disorders
3.3.1.3. Growing Adoption of Diagnostic Kits, Reagents with Antithrombin Deficiency.
3.3.1.4. Bleeding Episodes During Surgical Procedures.
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost of Antithrombin Therapy
3.3.2.2. Complication Associated with use of Oral Anticoagulants.
3.3.3. Opportunities
3.3.3.1. Technological Advancement and Rising Investment In R&D
3.3.3.2. Increasing Cardiovascular Disease & Ageing Population.
3.3.3.3. Increasing FDA Approval of Anticoagulants Drugs for Clinical Purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antithrombin Market Analysis and Forecast 2021-2031, By Source (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Human
4.1.2. Goat milk
4.1.3. Others
5. Global Antithrombin Market Analysis and Forecast 2021-2031, By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Therapeutics
5.1.2. Research
5.1.3. Diagnostics
5.1.4. Others
6. Global Antithrombin Market Analysis and Forecast, 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Anticoagulant
6.1.2. Antiplateletst
6.1.3. Thrombolytic Drugs
7. North America Antithrombin Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antithrombin Market Size and Forecast By Source
7.3. North America Antithrombin Market Size and Forecast By Application
7.4. North America Antithrombin Market Size and Forecast By Type
7.5. U.S. Antithrombin Market
7.5.1. Increasing Prevalence of CVD and Cancer in The Region, Boosting the Market.
7.6. Canada Antithrombin Market
7.6.1. Health Canada Has Approved Rivaroxaban to Prevent from Stroke, Myocardial Infarction, and Cardiovascular Death.
8. Europe Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antithrombin Market Size and Forecast By Source
8.3. Europe Antithrombin Market Size and Forecast By Application
8.4. Europe Antithrombin Market Size and Forecast By Type
8.5. UK Antithrombin Market
8.5.1. Rising risk of bleeding in high-risk surgery in the region.
8.6. Germany Antithrombin Market
8.6.1. Increasing use of antithrombin in the region.
8.7. France Antithrombin Market
8.7.1. Growing demand for stroke prevention in patients in the region.
8.8. Rest of Europe Antithrombin Market
9. Asia Pacific Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antithrombin Market Size and Forecast By Source
9.3. Asia Pacific Antithrombin Market Size and Forecast By Technology
9.4. Asia Pacific Antithrombin Market Size and Forecast By Type
9.5. China Antithrombin Market
9.5.1. Increasing cigarette consumption rate in the region.
9.6. India Antithrombin Market
9.6.1. Increasing awareness & expanding healthcare in the region.
9.7. Japan Antithrombin Market
9.7.1. Rising ageing population in the region.
9.8. Rest of Asia Pacific Antithrombin Market
10. Latin America Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antithrombin Market Size and Forecast By Source
10.3. Latin America Antithrombin Market Size and Forecast By Application
10.4. Latin America Antithrombin Market Size and Forecast By Type
10.4.1. Brazil Antithrombin Market
10.4.1.1. Arterial and venous thrombosis significantly impact morbidity and mortality.
10.4.2. Mexico Antithrombin Market
10.4.2.1. Rising need for screening and diagnosis of antithrombin deficiency.
10.4.3. Rest of Latin America Antithrombin Market
11. MEA Antithrombin Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antithrombin Market Size and Forecast By Source
11.3. MEA Antithrombin Market Size and Forecast By Application
11.4. MEA Antithrombin Market Size and Forecast By Type
11.5. South Africa Antithrombin Market
11.5.1.1. High incidence of mortality due to cancer, in the region.
11.6. Rest of MEA Antithrombin Market
12. Companies in the Antithrombin Market
12.1.1. Grifols, S.A
12.1.2. Company Snapshot
12.1.3. Company Overview
12.1.4. Financial Performance (2015-2020)
12.1.4.1. Net Revenue
12.1.4.2. Geographical Revenue, 2020
12.1.5. Product Offerings
12.1.6. Recent Initiatives (2017-2020)
12.2. Takeda Pharmaceutical Company Limited
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. LFB Biotechnologies S.A
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Scripps Laboratories
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Octapharma AG
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Thermo Fisher Scientific
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Siemens AG
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Axis-Shield Diagnostic Ltd
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Lee Bio solutions
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. CSL Limited
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antithrombin Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antithrombin Market Drivers & Restraints 2021
Table 7. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Human Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Goat milk Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Research Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Diagnostics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antithrombin Market Forecast By Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Anticoagulant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table63. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64 Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Antiplatelets Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Thrombolytic Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Regional Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antithrombin Market Forecast By Type 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table91. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94 North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 106. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table110. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 140. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 141. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 146. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159 Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 162. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. RoAPAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190 Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198 Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206 Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214 Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217 Leading 10 Antithrombin Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 218. Grifols, S.A Profile 2020 (CEO, HQ, Founded, Website)
Table 219. Grifols, S.A Antithrombin Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 220. Grifols, S.A Antithrombin Product Offering (Segment, Product Offerings)
Table 221. Baxter International Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 222. Baxter International Inc. Anticoagulants Product Offering (Segment, Product Offerings)
Table 223. Takeda Pharmaceutical Company Limited Profile 2020 (CEO, HQ, Founded, Website)
Table 224. Takeda Pharmaceutical Company Limited Antithrombin Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 225. Takeda Pharmaceutical Company Limited Antithrombin Product Offering (Segment, Product Offerings)
Table 226. LFB Biotechnologies S.A Profile 2020 (CEO, HQ, Founded, Website)
Table 227. LFB Biotechnologies S.A Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 228. LFB Biotechnologies S.A Antithrombin Product Offering (Segment, Product Offerings)
Table 229. Octapharma AG Profile 2020 (CEO, HQ, Founded, Website)
Table 230 Octapharma AG, Antithrombin Product Offering (Segment, Product Offerings)
Table 231. Thermo Fisher Scientific Profile 2020 (CEO, HQ, Founded, Website)
Table 232. Thermo Fisher Scientific Antithrombin Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 233 Thermo Fisher Scientific Antithrombin Product Offering (Segment, Product Offerings)
Table 234. Siemens AG Profile 2020 (CEO, HQ, Founded, Website)
Table 235. Siemens AG Antithrombin Product Offering (Segment, Product Offerings)
Table 236. Axis-Shield Diagnostic Ltd. Profile 2020 (CEO, HQ, Founded, Website)
Table 237. Axis-Shield Diagnostic Ltd Antithrombin Product Offering (Segment, Product Offerings)
Table 238. Lee Bio solutions Profile 2020 (CEO, HQ, Founded, Website)
Table 239. Lee Bio solutions Antithrombin Product Offering (Segment, Product Offerings)
Table 240. CSL Limited Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 241. CSL Limited Total Company Sales 2015-2020 (US$M, AGR %)
Table 242. CSL Limited Product Offering (Segment, Product Offerings)
Table 243. Other Companies Involved in the Antithrombin Market (Company, Location)
LIST OF FIGURES
Figure 1. Antithrombin Market Type Overview
Figure 2. Antithrombin Market By Source Overview
Figure 3. Antithrombin Market By Application Overview
Figure 4. Antithrombin Market By Type Overview
Figure 5 Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antithrombin Submarket Forecast By Source 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antithrombin Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antithrombin Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antithrombin Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antithrombin Market Forecast By Source 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antithrombin Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antithrombin Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 61. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antithrombin Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 141. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antithrombin Market Forecast By Source2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M)
Figure 151. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M)
Figure 161. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antithrombin Market Forecast By Source 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antithrombin Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M)
Figure 171. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antithrombin Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antithrombin Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
15. China Biologic Products Holdings, Inc.
16. Lundbeck Inc
17. Axon Lab AG
18. Affinity Biologicals, Inc.
19. Sigma-Aldrich, Inc.
20. Abbott Laboratories
21. Baxter International Inc.
22. AstraZeneca plc
23. Bayer AG.
24. Boehringer Ingelheim GmbH
25. Eli Lilly and Company
26. Bristol-Myers Squibb Company
27. Merck & Co., Inc.
28. Genentech Inc.
29. GlaxoSmithKline plc
30. Pfizer, Inc.
31. Sanofi S.A
32. Novartis AG
33. Daiichi Sankyo Company
34. Aspen Holdings
35. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
36. Portola Pharmaceuticals, Inc.
37. Lunac Therapeutics
38. The Medicines
39. United Therapeutics
40. Otsuka Pharmaceutical
Companies Profiled in the Report
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
List of Companies Mentioned in the Report:
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
15. China Biologic Products Holdings, Inc.
16. Lundbeck Inc
17. Axon Lab AG
18. Affinity Biologicals, Inc.
19. Sigma-Aldrich, Inc.
20. Abbott Laboratories
21. Baxter International Inc.
22. Astrazeneca plc
23. Bayer AG.
24. Boehringer Ingelheim GmbH
25. Eli Lilly and Company
26. Bristol-Myers Squibb Company
27. Merck & Co., Inc.
28. Genentech Inc.
29. GlaxoSmithKline plc
30. Pfizer, Inc.
31. Sanofi S.A
32. Novartis AG
33. Daiichi Sankyo Company
34. Aspen Holdings
35. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
36. Portola Pharmaceuticals, Inc.
37. Lunac Therapeutics
38. The Medicines
39. United Therapeutics
40. Otsuka Pharmaceutical
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. National Blood Clot Alliance
4. the American Association for Cancer Research.
5. Organic Process Research & Development
6. The National Cancer Survivorship Resource Center
7. US Food & Drug Administration
8. US National Library of Medicine
9. National Institutes of Health
10. National Organisation for Rare Diseases
11. National Association for Biomedical Research
12. Center for Disease Control and Prevention CDC
13. Journal of the American college of Cardiology
14. National Association of Orthopaedic Nurses
15. National Foundation for Infectious Diseases.
16. Clinical Infectious Diseases
17. American Association for Cancer Research.
18. Center for Diseases Dynamics, Economics & Policy (CDDEP)
19. The American Society of Hematology in Orlando
20. The Global Health Security Agenda (GHSA)
21. American Cancer Society.
22. World Cancer Research Fund
23. National Cancer Institute
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
List of Companies Mentioned in the Report:
1. Grifols, S.A
2. Takeda Pharmaceutical Company Limited
3. LFB Biotechnologies S.A
4. Scripps Laboratories,
5. Octapharma AG,
6. Thermo Fisher Scientific
7. Siemens AG
8. Axis-Shield Diagnostic Ltd.
9. Lee Bio solutions
10. CSL Limited
11. Kedrion S.p.A.
12. Dem ilac Inc
13. Kyowa Kirin Co., Ltd.
14. Diapharma Group, Inc.
15. China Biologic Products Holdings, Inc.
16. Lundbeck Inc
17. Axon Lab AG
18. Affinity Biologicals, Inc.
19. Sigma-Aldrich, Inc.
20. Abbott Laboratories
21. Baxter International Inc.
22. Astrazeneca plc
23. Bayer AG.
24. Boehringer Ingelheim GmbH
25. Eli Lilly and Company
26. Bristol-Myers Squibb Company
27. Merck & Co., Inc.
28. Genentech Inc.
29. GlaxoSmithKline plc
30. Pfizer, Inc.
31. Sanofi S.A
32. Novartis AG
33. Daiichi Sankyo Company
34. Aspen Holdings
35. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
36. Portola Pharmaceuticals, Inc.
37. Lunac Therapeutics
38. The Medicines
39. United Therapeutics
40. Otsuka Pharmaceutical
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. National Blood Clot Alliance
4. the American Association for Cancer Research.
5. Organic Process Research & Development
6. The National Cancer Survivorship Resource Center
7. US Food & Drug Administration
8. US National Library of Medicine
9. National Institutes of Health
10. National Organisation for Rare Diseases
11. National Association for Biomedical Research
12. Center for Disease Control and Prevention CDC
13. Journal of the American college of Cardiology
14. National Association of Orthopaedic Nurses
15. National Foundation for Infectious Diseases.
16. Clinical Infectious Diseases
17. American Association for Cancer Research.
18. Center for Diseases Dynamics, Economics & Policy (CDDEP)
19. The American Society of Hematology in Orlando
20. The Global Health Security Agenda (GHSA)
21. American Cancer Society.
22. World Cancer Research Fund
23. National Cancer Institute
Download sample pages
Complete the form below to download your free sample pages for Antithrombin Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Antithrombin Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
